Convagran 50 mg 30 capsules
123£
View analogsMonotherapy in adult patients with newly diagnosed epilepsy presenting with partial epileptic seizures with or without secondary generalization.
Adjunctive therapy in adults, adolescents, and children aged 6 years and older with partial epileptic seizures with or without secondary generalization.
Form of Release: Capsules
Product Brand:
Mash Premiere for Pharmaceutical Industries
About the brand
Product Categories: Brain and cerebral circulation • Epilepsy
Convagran 50 mg 30 capsules
Composition:
Active Ingredient: Zonisamide — 50 mg per capsule.
Excipients: Hydrogenated vegetable oil, microcrystalline cellulose (MCC), sodium lauryl sulfate.
Product Description:
- Zonisamide is an antiepileptic agent, a benzisoxazole derivative, which weakly inhibits carbonic anhydrase in vitro.
- Chemically, its structure differs from other antiepileptic drugs.
- The mechanism of action of zonisamide is not fully understood;
- it likely blocks voltage-gated sodium and calcium channels, reduces the intensity of synchronized neuronal excitation, inhibits seizure development, and prevents the further spread of epileptic activity.
- Zonisamide also reduces neuronal seizure activity by enhancing the inhibitory effect of GABA.
Indications for Use:
Monotherapy in adult patients with newly diagnosed epilepsy presenting with partial epileptic seizures with or without secondary generalization.
Adjunctive therapy in adults, adolescents, and children aged 6 years and older with partial epileptic seizures with or without secondary generalization.
Method of Administration and Dosage:
- Administered orally with water, with or without food.
- The dosage is individualized based on therapeutic effect.
- The effective daily dose ranges from 300 mg to 500 mg, although some patients, particularly those not taking CYP3A4-inducing drugs, may respond to lower doses.
- The initial daily dose is 50 mg, divided into two doses.
- After one week, the daily dose may be increased to 100 mg per day.
- Thereafter, the dose may be increased by 100 mg every 7 days up to the maximum recommended daily dose of 500 mg.
- Subsequently, a transition to a single daily dose may be considered during treatment.
- For patients with hepatic or renal impairment, as well as those not taking CYP3A4 inducers, dose titration intervals of two weeks should be considered.
Contraindications:
- Hypersensitivity to zonisamide, any excipients, or sulfonamides.
- Age under 18 years for monotherapy and under 6 years for adjunctive therapy.
- Severe hepatic impairment.
- Acute renal failure or clinically indicated persistent increase in serum creatinine.
- Pregnancy.
- Lactation (breastfeeding).
Precautions:
- Discontinuation of Convagran is recommended in patients who develop skin rashes that cannot be attributed to other causes.
- All patients who develop skin rashes should be closely monitored, especially those receiving concomitant antiepileptic drugs known to cause rashes.
- Treatment should be withdrawn by gradual dose reduction to avoid withdrawal syndrome and precipitation of epileptic seizures.
- Caution is required when transitioning patients from adjunctive therapy to Convagran monotherapy.
Adverse Reactions / Side Effects:
Convagran contains a sulfonamide group, which may cause serious immune-mediated adverse reactions, including skin rashes, allergic reactions, and severe hematological disorders (such as aplastic anemia).
The most common adverse reactions reported during combination therapy trials were somnolence, dizziness, and anorexia. In monotherapy, decreased bicarbonate levels, loss of appetite, and weight loss were frequently observed.
Pregnancy and Lactation:
The use of Convagran during pregnancy is contraindicated due to the potential risk of teratogenicity.
If administration during lactation is necessary, breastfeeding must be discontinued.
Storage Conditions:
Store at a temperature not exceeding 30 °C in a dry place, protected from light.
Keep out of reach of children.
Packaging:
Cardboard box containing 3 blisters of 10 capsules each.
Tags, Keywords:
Active Ingredients:
No comments yet. Be the first to write one.
Your comment will be published after moderation.
You’ll receive a notification to your email when someone replies.
Русский
English
عربي


